What is HC Wainwright’s Forecast for Clene Q1 Earnings?

Clene Inc. (NASDAQ:CLNN) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Clene in a research report issued on Thursday, March 12th. HC Wainwright analyst J. Pantginis anticipates that the company will post earnings per share of ($0.45) for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.19) per share. HC Wainwright also issued estimates for Clene’s Q2 2026 earnings at ($0.48) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.45) EPS.

Clene (NASDAQ:CLNN) last released its quarterly earnings data on Thursday, March 12th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.14). The firm had revenue of $0.08 million during the quarter, compared to analyst estimates of $0.03 million.

CLNN has been the subject of a number of other research reports. D. Boral Capital restated a “buy” rating and issued a $23.00 price objective on shares of Clene in a research note on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Clene in a research report on Friday, January 9th. UBS Group reissued a “buy” rating on shares of Clene in a research note on Wednesday, December 3rd. Benchmark reissued a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $48.00 price target on shares of Clene in a research note on Friday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $32.60.

Clene Price Performance

Shares of CLNN stock opened at $5.95 on Monday. Clene has a one year low of $2.28 and a one year high of $13.50. The stock has a fifty day moving average price of $4.99 and a 200 day moving average price of $6.72. The stock has a market cap of $64.56 million, a P/E ratio of -2.29 and a beta of 0.62.

Hedge Funds Weigh In On Clene

Several large investors have recently made changes to their positions in the company. SymBiosis Capital Partners LLC bought a new position in Clene in the fourth quarter valued at about $4,523,000. Scoggin Management LP increased its position in Clene by 75.1% in the third quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock worth $1,506,000 after purchasing an additional 107,250 shares during the period. Ensign Peak Advisors Inc raised its holdings in Clene by 668.6% during the 4th quarter. Ensign Peak Advisors Inc now owns 114,361 shares of the company’s stock worth $671,000 after purchasing an additional 99,481 shares during the last quarter. PEAK6 LLC bought a new stake in Clene during the 4th quarter worth about $294,000. Finally, State Street Corp lifted its position in Clene by 138.4% during the 4th quarter. State Street Corp now owns 29,801 shares of the company’s stock valued at $175,000 after purchasing an additional 17,300 shares during the period. Institutional investors and hedge funds own 23.28% of the company’s stock.

Insider Activity

In other news, major shareholder Chidozie Ugwumba sold 32,705 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The shares were sold at an average price of $5.50, for a total transaction of $179,877.50. Following the transaction, the insider directly owned 708,587 shares in the company, valued at approximately $3,897,228.50. This represents a 4.41% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David J. Matlin acquired 33,333 shares of the company’s stock in a transaction that occurred on Tuesday, January 13th. The stock was bought at an average price of $6.50 per share, with a total value of $216,664.50. Following the transaction, the director directly owned 477,824 shares in the company, valued at $3,105,856. The trade was a 7.50% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last quarter, insiders have sold 276,144 shares of company stock worth $1,474,306. 35.30% of the stock is owned by corporate insiders.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).